Moleculin Biotech, Inc. (NASDAQ: MBRX)

Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, is engaged in the development of next-generation anti-cancer drug candidates. Notably, the world’s largest cancer research facility, M.D. Anderson Cancer Center, was a key part of the discovery process that resulted in some of the candidates in the company’s development pipeline and it continues to collaborate with the company today.

Annamycin, the lead product candidate, is a Phase II clinical stage clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia (AML). Designed to eliminate cardiotoxicity for far greater market reach and avoid the multidrug resistance mechanisms that often defeat current anthracyclines, Annamycin has far greater potential than currently approved induction therapy drugs. It has also been shown to be non-cardiotoxic in animal models when compared with doxorubicin, one of the leading anthracyclines used for induction therapy in acute leukemia patients with reported annual revenues exceeding $700 million.

WP1066 has shown a high level of activity against a wide range of solid tumors, including prostate, head & neck, pancreatic, breast, ovarian and metastatic melanoma. The drug candidate amplifies the tumor-fighting properties of the natural compound it is modeled after to potent levels and, very importantly, can cross the blood-brain barrier. It also appears to be uniquely capable in vitro of both stimulating a natural immune response and directly killing tumor cells to block tumor progression.

WP122 is an anti-cancer drug candidate that can inhibit glucose metabolism, which is an important driver of glycolytic brain tumor progression and survival. The candidate has received significant attention from the scientific community as a promising new approach to treating brain tumors, partially due to its unusual nature that allows for high brain uptake and retention. WP1122 has been shown both in vitro and in vivo to induce a destruction of glioma cells, the most aggressive form of brain tumor.

Moleculin Biotech’s development strategy includes targeting orphan drugs with high revenue potential, pursuing game-changing breakthroughs, minimizing cash burn through a virtual structure, and creating proprietary positioning for all projects through worldwide exclusive licenses and regulatory exclusivity. Led by a team of well-respected leaders with proven ability to create disruptive technology, the company has positioned itself to become a leading player in the $100+ billion market for cancer treatments.

Investment Considerations
  • Multiple game-changing drug candidates with blockbuster potential in oncology markets
  • Ongoing collaboration with one of the largest cancer centers in the world
  • Leadership team comprised of veteran pharma/biotech and life science professionals
  • High insider ownership aligns management interests with shareholders
Additional Resources